Sunitinib Shows Activity in Mucosal, Acral Melanoma

Share this content:
Sunitinib showed activity in the treatment of mucosal and acral melanoma whether or not the patients had a KIT mutation.
Sunitinib showed activity in the treatment of mucosal and acral melanoma whether or not the patients had a KIT mutation.

Sunitinib showed activity in the treatment of mucosal and acral melanoma whether or not the patients had a KIT mutation, according to a new study published online ahead of print in the journal Cancer; however, it was poorly tolerated and no patient experienced a prolonged response.

Patients with mucosal and acral melanoma have limited treatment options available to them and a poor prognosis. Some patients with this subtype of skin cancer possess a mutation in the KIT oncogene, which can be targeted by the kinase inhibitor, sunitinib.

For the multicenter phase 2 trial, researchers enrolled 52 patients with unresectable stage 3 or 4 mucosal or acral melanoma. Patients were assigned to receive either sunitinib 50 mg daily for 4 weeks of a 6-week cycle or sunitinib 37.5 mg daily continuously.

Results showed that four patients achieved partial responses lasting between 5 and 10 months. Of those, one patient possessed a KIT mutation.

Researchers found that 52% (95% CI: 38, 66) of patients in both groups were alive and progression-free at 2 months, which was significantly larger than the researchers expected.

RELATED: In Melanoma, Adjuvant Lymph Node Field Radiotherapy Does Not Impact Survival

However, the study demonstrated no significant difference in response or overall survival between the 25% of patients with a KIT mutation compared with those without one.

In regard to safety, the researchers observed a high rate of toxicity associated with sunitinib treatment in both groups.

Reference

  1. Buchbinder EI, Sosman JA, Lawrence DP, et al. Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. Cancer. 2015. [epub ahead of print]. doi: 10.1002/cncr.29622.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters